REG - Destiny Pharma PLC - Posting of Annual Report and Notice of AGM

Destiny PharmaAnnouncement

27/04/2022 15:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220427:nRSa5813Ja&default-theme=true

RNS Number : 5813J  Destiny Pharma PLC  27 April 2022

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Posting of Annual Report and Accounts, and Notice of AGM

 

 

Brighton, United Kingdom - 27 April 2022 - Destiny Pharma plc (AIM: DEST) a
clinical stage innovative biotechnology company focused on the development of
novel medicines that can prevent life-threatening infections, announces that
the following documents are now available on the Company's website
at www.destinypharma.com (http://www.destinypharma.com)

 

•    Annual Report and Accounts of the Company for the year ended 31
December 2021

 

•    Notice of the 2022 Annual General Meeting ("AGM") which is to be
held at 11.00 a.m. on 27 May, 2022 at the offices of finnCap Ltd, One
Bartholomew Close, London, EC1A 7BL

 

Printed copies of both documents will be posted to shareholders today.

 

For those shareholders unable to attend the AGM in person, the Company will
operate a virtual facility to allow shareholders to listen in to the business
of the AGM.  However, shareholders will not be able to vote online during the
meeting and are therefore urged to submit their votes via proxy as early as
possible.

 

The Company is using the Investor Meet Company platform. This platform will
allow shareholders to follow proceedings of the AGM and hear from the Company
via the live presentation and Q&A session immediately following the AGM.
The Company will also provide an online recording, available on the Investor
Meet Company platform after the meeting.

 

Shareholders are invited to pre-submit questions online via the Investor Meet
Company platform up until 11.00 a.m. on 26 May 2022, being the day before the
AGM, or during the AGM itself via the Q&A function. Please include the
Shareholder's name and Shareholder Reference Number (which can be found on the
share certificate or proxy form).

 

Shareholders who wish to attend the AGM online should register for the event
in advance via the following
link: https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
(https://www.investormeetcompany.com/destiny-pharma-plc/register-investor) .

 

For further information, please contact:

 

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Optimum Strategic Communications

Mary Clark / Manel Mateus / Vici Rabbetts

+44 (0) 208 078 4357

DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)

 

finnCap Ltd (Nominated Advisor and Broker)

Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

About Destiny Pharma

 

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2b clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SPOR-COV, a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF research projects.

 

For further information on the company, please visit  www.destinypharma.com
(http://www.destinypharma.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAIRMITMTJTBTT